The DEA Built a Cannabis Rescheduling Hearing Where Only One Side Gets to Talk

The DEA is holding a hearing right now on whether to move cannabis out of Schedule I, the legal category reserved for drugs the government says have no accepted medical use. Seven witnesses were selected to testify. All seven oppose rescheduling. Nobody arguing the other side of the government’s own proposal got a seat.

A hearing designed to test evidence isn’t testing anything if only one side is allowed to submit it.

The hearing runs through July 15, and the fight over its legitimacy escalated this week when the Justice Department filed a brief on July 3 opposing a drug-testing industry group and a pharmaceutical company that wanted to pause the whole proceeding. DOJ’s language was not diplomatic: “Congress did not enact the CSA to provide drug screeners with a permanent source of income for testing marijuana,” the brief argued, accusing the petitioners of “pocketbook interests” — meaning, bluntly, that a rescheduled cannabis market would shrink the workplace-drug-testing industry’s business, and that’s the real objection dressed up as a procedural one.

Here’s what almost nobody covering this fight is saying plainly: DOJ is right that the petitioners’ motives look transparently commercial. That doesn’t make the hearing structure defensible. Both things are true. A federal drug-scheduling process is supposed to be the place where the government’s own evidence gets pressure-tested by people who disagree with it — that’s the entire point of a hearing instead of a memo. Stacking the witness list with one side and then loudly defending the stack in court isn’t evidence-based policymaking. It’s a verdict wearing a hearing’s clothes.

For treatment providers and case managers whose clients are navigating cannabis use disorder or co-occurring conditions, the practical stakes are real regardless of how this hearing shakes out: Schedule III would ease research restrictions that have throttled clinical study of cannabis for decades, which is exactly the kind of evidence a fair hearing would want more of, not less. Rize has covered the scheduling fight’s science and policy fault lines all year; this is the version where the process itself became the story.

Millions of people use cannabis daily under state law that federal scheduling still contradicts. They deserve a rescheduling decision built on a real hearing, not a pre-written one.